Fig. 4.

Ago2-deficiency in the liver improves glucose metabolism in obesity. a Body weights of L-Ago2 WT (n = 16) and KO (n = 17) mice fed HFD, and L-Ago2 WT (n = 15) and KO (n = 11) mice fed CD, starting in 4 weeks of age. b GTT performed in L-Ago2 WT (n = 16) and KO (n = 17) mice fed HFD at 20 weeks of age. c ITT performed in L-Ago2 WT (n = 16) and KO (n = 17) mice fed HFD at 14 weeks of age. d PTT performed in L-Ago2 WT (n = 8) and KO (n = 8) mice fed HFD at 17 weeks of age. e–h Hyperinsulinemic-euglycemic clamp studies performed in L-Ago2 WT (n = 6) and L-Ago2 KO (n = 10) mice fed HFD for 20 weeks. e Glucose infusion rates (GIR) throughout the clamp procedures. The graph on the right shows an integrated area under curves (AUC) of GIR. f Insulin clearance levels during the clamp. g Tissue glucose uptakes in gastrocnemius muscle, visceral fat, and subcutaneous fat tissues. h Suppression of hepatic glucose production (sHGP) during the clamp. Data are shown as the mean ± SEM. *p < 0.05, **p < 0.01